Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
| February 28, 2024
Read More
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
| November 14, 2023
Read More
Vivani Medical to Present at BIO Investor Forum
| October 16, 2023
Read More
Vivani Medical to Present at the Boulder Peptide Symposium
| September 7, 2023
Read More
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
| September 5, 2023
Read More
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
| August 14, 2023
Read More
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
| July 11, 2023
Read More
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
| June 14, 2023
Read More
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
| June 14, 2023
Read More
Vivani Medical Reports First Quarter Financial Results and Provides Business Update
| May 16, 2023
Read More
Blog Navigation
Contact Us
To learn more about Vivani or LIBERATE-1, the upcoming First-in-Human trial of our long-term GLP-1 implant, please fill out the form.